{"id":49896,"date":"2025-12-03T22:34:39","date_gmt":"2025-12-03T14:34:39","guid":{"rendered":"https:\/\/flcube.com\/?p=49896"},"modified":"2025-12-03T22:34:40","modified_gmt":"2025-12-03T14:34:40","slug":"msd-mk-2214-fast-track-alzheimer-data-positive","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49896","title":{"rendered":"MSD MK-2214 Fast Track Alzheimer Data Positive"},"content":{"rendered":"\n<p><strong>Merck Sharp &amp;\u202fDohme Inc.<\/strong> (MSD, <a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:NYSE\">NYSE: MRK<\/a>) released first\u2011in\u2011human data for <strong>MK-2214<\/strong> and <strong>MK-1167<\/strong> in Alzheimer\u2019s disease (AD), while announcing that <strong>MK-2214<\/strong> has been granted <strong>FDA Fast Track Designation<\/strong> for AD treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-drug-profile\">Regulatory Milestone &amp; Drug Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Target<\/th><th>Mechanism<\/th><th>Regulatory Status<\/th><\/tr><\/thead><tbody><tr><td><strong>MK-2214<\/strong><\/td><td>Phosphorylated serine 413 (pS413) tau<\/td><td>Novel antibody (co\u2011developed with Teijin Pharma)<\/td><td>FDA Fast Track Designation granted<\/td><\/tr><tr><td><strong>MK-1167<\/strong><\/td><td>Alpha\u20117 (\u03b17) nicotinic acetylcholine receptor<\/td><td>Oral positive allosteric modulator<\/td><td>Phase 1 completed; Phase 2 ongoing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mk-2214-phase-1-data-amp-development-path\">MK-2214: Phase 1 Data &amp; Development Path<\/h2>\n\n\n\n<p><strong>Study Design<\/strong>: Three Phase 1 studies in healthy volunteers and individuals with mild cognitive impairment and mild\u2011to\u2011moderate AD<\/p>\n\n\n\n<p><strong>Key Findings<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Safety &amp; Tolerability<\/strong>: Favorable profile across all dose cohorts<\/li>\n\n\n\n<li><strong>Pharmacokinetics<\/strong>: Linear PK supporting once\u2011monthly subcutaneous dosing<\/li>\n\n\n\n<li><strong>Target Engagement<\/strong>: Demonstrated robust reduction of pS413 tau in CSF<\/li>\n<\/ul>\n\n\n\n<p><strong>Next Steps<\/strong>: Phase 2\/3 study initiation planned for Q2\u202f2026<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mk-1167-phase-1-study-amp-dose-selection\">MK-1167: Phase 1 Study &amp; Dose Selection<\/h2>\n\n\n\n<p><strong>Study Design<\/strong>: First\u2011in\u2011human single\u2011dose study in healthy adult male volunteers<\/p>\n\n\n\n<p><strong>Key Findings<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Glutamate Metabolism<\/strong>: Measurable effect on prefrontal cortex glutamate levels, supporting mechanism of action<\/li>\n\n\n\n<li><strong>Safety<\/strong>: Well\u2011tolerated at all tested doses<\/li>\n\n\n\n<li><strong>PK\/PD<\/strong>: Dose\u2011dependent receptor occupancy established<\/li>\n<\/ul>\n\n\n\n<p><strong>Clinical Relevance<\/strong>: Data informed dose selection for ongoing <strong>Phase 2 trial<\/strong> in AD patients<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-alzheimer-s-market-context-amp-strategic-outlook\">Alzheimer\u2019s Market Context &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Disease Burden<\/strong>: 6.5 million AD patients in US; global market projected <strong>$10\u202fbillion<\/strong> by 2030<\/li>\n\n\n\n<li><strong>Tau Pathway<\/strong>: pS413 tau represents novel epitope for intervention; MK-2214 offers differentiated approach vs. anti\u2011amyloid antibodies<\/li>\n\n\n\n<li><strong>Fast Track Impact<\/strong>: Accelerates review timeline; enables rolling submission and more frequent FDA interaction<\/li>\n\n\n\n<li><strong>Combination Potential<\/strong>: \u03b17 nicotinic modulation (MK-1167) may provide symptomatic benefit while MK-2214 targets disease progression<\/li>\n\n\n\n<li><strong>Pipeline Value<\/strong>: Two mechanistically distinct assets position MSD as leader in next\u2011generation AD therapeutics<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding MK-2214 and MK-1167 development timelines, clinical outcomes, and regulatory interactions. Actual results may differ due to clinical, regulatory, and competitive uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck Sharp &amp;\u202fDohme Inc. (MSD, NYSE: MRK) released first\u2011in\u2011human data for MK-2214 and MK-1167 in&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49897,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,2675,176,903,80],"class_list":["post-49896","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk","tag-priority-reviews"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>MSD MK-2214 Fast Track Alzheimer Data Positive - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck Sharp &amp;\u202fDohme Inc. (MSD, NYSE: MRK) released first\u2011in\u2011human data for MK-2214 and MK-1167 in Alzheimer\u2019s disease (AD), while announcing that MK-2214 has been granted FDA Fast Track Designation for AD treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49896\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MSD MK-2214 Fast Track Alzheimer Data Positive\" \/>\n<meta property=\"og:description\" content=\"Merck Sharp &amp;\u202fDohme Inc. (MSD, NYSE: MRK) released first\u2011in\u2011human data for MK-2214 and MK-1167 in Alzheimer\u2019s disease (AD), while announcing that MK-2214 has been granted FDA Fast Track Designation for AD treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49896\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-03T14:34:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-03T14:34:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0308.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49896#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49896\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MSD MK-2214 Fast Track Alzheimer Data Positive\",\"datePublished\":\"2025-12-03T14:34:39+00:00\",\"dateModified\":\"2025-12-03T14:34:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49896\"},\"wordCount\":320,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49896#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0308.webp\",\"keywords\":[\"Clinical trial results\",\"Merck Sharp &amp; Dohme\",\"MSD\",\"NYSE: MRK\",\"Priority reviews\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49896#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49896\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49896\",\"name\":\"MSD MK-2214 Fast Track Alzheimer Data Positive - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49896#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49896#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0308.webp\",\"datePublished\":\"2025-12-03T14:34:39+00:00\",\"dateModified\":\"2025-12-03T14:34:40+00:00\",\"description\":\"Merck Sharp &\u202fDohme Inc. (MSD, NYSE: MRK) released first\u2011in\u2011human data for MK-2214 and MK-1167 in Alzheimer\u2019s disease (AD), while announcing that MK-2214 has been granted FDA Fast Track Designation for AD treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49896#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49896\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49896#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0308.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0308.webp\",\"width\":1080,\"height\":608,\"caption\":\"MSD MK-2214 Fast Track Alzheimer Data Positive\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49896#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MSD MK-2214 Fast Track Alzheimer Data Positive\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MSD MK-2214 Fast Track Alzheimer Data Positive - Insight, China&#039;s Pharmaceutical Industry","description":"Merck Sharp &\u202fDohme Inc. (MSD, NYSE: MRK) released first\u2011in\u2011human data for MK-2214 and MK-1167 in Alzheimer\u2019s disease (AD), while announcing that MK-2214 has been granted FDA Fast Track Designation for AD treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49896","og_locale":"en_US","og_type":"article","og_title":"MSD MK-2214 Fast Track Alzheimer Data Positive","og_description":"Merck Sharp &\u202fDohme Inc. (MSD, NYSE: MRK) released first\u2011in\u2011human data for MK-2214 and MK-1167 in Alzheimer\u2019s disease (AD), while announcing that MK-2214 has been granted FDA Fast Track Designation for AD treatment.","og_url":"https:\/\/flcube.com\/?p=49896","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-03T14:34:39+00:00","article_modified_time":"2025-12-03T14:34:40+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0308.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49896#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49896"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MSD MK-2214 Fast Track Alzheimer Data Positive","datePublished":"2025-12-03T14:34:39+00:00","dateModified":"2025-12-03T14:34:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49896"},"wordCount":320,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49896#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0308.webp","keywords":["Clinical trial results","Merck Sharp &amp; Dohme","MSD","NYSE: MRK","Priority reviews"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49896#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49896","url":"https:\/\/flcube.com\/?p=49896","name":"MSD MK-2214 Fast Track Alzheimer Data Positive - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49896#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49896#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0308.webp","datePublished":"2025-12-03T14:34:39+00:00","dateModified":"2025-12-03T14:34:40+00:00","description":"Merck Sharp &\u202fDohme Inc. (MSD, NYSE: MRK) released first\u2011in\u2011human data for MK-2214 and MK-1167 in Alzheimer\u2019s disease (AD), while announcing that MK-2214 has been granted FDA Fast Track Designation for AD treatment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49896#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49896"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49896#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0308.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0308.webp","width":1080,"height":608,"caption":"MSD MK-2214 Fast Track Alzheimer Data Positive"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49896#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MSD MK-2214 Fast Track Alzheimer Data Positive"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0308.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49896","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49896"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49896\/revisions"}],"predecessor-version":[{"id":49898,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49896\/revisions\/49898"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49897"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49896"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49896"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49896"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}